文献速递胸部肿瘤

色瑞替尼治疗ROS1重排非小细胞肺癌患者的开放标签、多中心、II期研究

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
PubMed 文献 · J Clin Oncol · 2017-05-18

该研究纳入32例经FISH检测ROS1重排阳性的晚期非小细胞肺癌患者,给予色瑞替尼750 mg每日一次口服。客观缓解率为62%(95% CI 45%至77%),中位缓解持续时间21.0个月,中位无进展生存期9.3个月,中位总生存期24个月。常见不良事件为腹泻(78%)、恶心(59%)和食欲减退(56%),多为1或2级。

要点

  • 色瑞替尼750 mg每日一次在ROS1重排非小细胞肺癌中客观缓解率达62%。
  • 中位无进展生存期9.3个月,初治患者达19.3个月。
  • 8例脑转移患者中5例(63%)获颅内疾病控制。

核心结论

  • 色瑞替尼在既往接受过多线化疗的ROS1重排非小细胞肺癌患者中显示出强效临床活性。

研究设计与样本

  • 开放标签、多中心、II期研究,纳入32例经荧光原位杂交(FISH)检测ROS1重排阳性的晚期非小细胞肺癌患者。
  • 色瑞替尼750 mg每日一次口服,主要终点为客观缓解率。

主要发现

  • 客观缓解率为62%(95% CI 45%至77%),其中完全缓解1例、部分缓解19例。
  • 缓解持续时间为21.0个月(95% CI 17至25个月),疾病控制率为81%(95% CI 65%至91%)。
  • 全部患者中位无进展生存期为9.3个月(95% CI 0至22个月),初治患者为19.3个月(95% CI 1至37个月)。
  • 中位总生存期为24个月(95% CI 5至43个月)。
  • 8例脑转移患者中,5例(63%;95% CI 31%至86%)报告颅内疾病控制。

关键数值与推荐

  • 常见不良事件(多为1或2级)包括腹泻(78%)、恶心(59%)和食欲减退(56%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose ROS1 rearrangement is a distinct molecular subset of non-small-cell lung cancer (NSCLC). We investigated the efficacy and safety of ceritinib in patients with ROS1-rearranged NSCLC. Patients and Methods We enrolled 32 patients with advanced NSCLC who tested positive for ROS1 rearrangement by fluorescent in situ hybridization. Ceritinib 750 mg was administered once daily. The primary end point was objective response rate. The secondary end points were disease control rate; duration of response; progression-free survival; overall survival; toxicity; and concordance among fluorescent in situ hybridization, immunohistochemistry, and next-generation sequencing. Results Between June 7, 2013, and February 1, 2016, 404 patients underwent ROS1 prescreening, and 32 patients with ROS1 rearrangement were enrolled. All patients except two were crizotinib-naïve. At the time of data cutoff, the median follow-up was 14.0 months, and 18 patients (56%) had discontinued treatment. Of the 32 patients enrolled, 28 were evaluable for response by independent radiologic review. Objective response rate was 62% (95% CI, 45% to 77%), with one complete response and 19 partial responses; duration of response was 21.0 months (95% CI, 17 to 25 months); and disease control rate was 81% (95% CI, 65% to 91%). The median progression-free survival was 9.3 months (95% CI, 0 to 22 months) for all patients and 19.3 months (95% CI, 1 to 37 months) for crizotinib-naïve patients. The median overall survival was 24 months (95% CI, 5 to 43 months). Of the eight patients with brain metastases, intracranial disease control was reported in five (63%; 95% CI, 31% to 86%). The most common adverse events (majority, grade 1 or 2) for all treated patients were diarrhea (78%), nausea (59%), and anorexia (56%). Conclusion Ceritinib demonstrated potent clinical activity in patients with ROS1-rearranged NSCLC who were heavily treated previously with multiple lines of chemotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lim SM, Kim HR, Lee JS, et al. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol. 2017. PMID: 28520527. doi:10.1200/JCO.2016.71.3701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。